Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing new smallpox vaccines.

S R Rosenthal1, M Merchlinsky, C Kleppinger

  • 1CBER/Food and Drug Administration, Rockville, MD 20852, USA. rosenthals@cber.fda.gov

Emerging Infectious Diseases
|December 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis B in the United States: ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007.

Infection·2012
Same author

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

Vaccine·2011
Same author

Infectiousness of the closed case of tuberculosis.

American journal of public health and the nation's health·2010
Same author

The contagiousness of coccidioidomycosis; an experimental study.

The American journal of pathology·2010
Same author

Contagiousness of coccidioidomycosis; an experimental study.

Archives of internal medicine (Chicago, Ill. : 1908)·2010
Same author

The contagiousness of coccidioidomycosis.

Proceedings [of the] annual meeting. Central Society for Clinical Research (U.S.)·2010
Same journal

Detection of and Early Genomic Insights into Chikungunya Virus, Bolivia, 2025.

Emerging infectious diseases·2026
Same journal

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same journal

New World Ocular Dirofilariasis Caused by Dirofilaria repens Infection, United States.

Emerging infectious diseases·2026
Same journal

Angiostrongylus cantonensis Rat Lungworm Detected in Rats, Madagascar, 2022-2023.

Emerging infectious diseases·2026
Same journal

Human Pulmonary Dirofilariasis,
North Queensland, Australia, 2023<sup>1</sup>.

Emerging infectious diseases·2026
Same journal

Trends in Congenital Syphilis Cases by Maternal Country of Birth, Spain, 2016-2024.

Emerging infectious diseases·2026
See all related articles

New smallpox vaccines are needed for security. Current vaccines use calf-grown Vaccinia virus (VACV), but new cell-substrate grown vaccines offer improved safety and manufacturing control.

Area of Science:

  • Virology
  • Vaccinology
  • Regulatory Science

Background:

  • Current smallpox vaccine stockpiles rely on live Vaccinia virus (VACV) propagated in calves.
  • This traditional method presents manufacturing control challenges and potential safety concerns.
  • New threats necessitate updated vaccine strategies for civilian and military protection.

Purpose of the Study:

  • To review regulatory considerations for new smallpox vaccine development.
  • To discuss adverse events linked to calf lymph-propagated smallpox vaccine.
  • To examine cell substrate selection and safety/efficacy demonstration for novel vaccines.

Main Methods:

  • Review of regulatory guidelines and scientific literature.
  • Analysis of adverse event data from historical smallpox vaccination.

Related Experiment Videos

  • Evaluation of cell substrate technologies for viral propagation.

    • Main Results:

    • Identification of various Vaccinia virus strains used in vaccines.
    • Summary of adverse events associated with calf lymph-derived vaccines.
    • Discussion of challenges in selecting and validating cell substrates for vaccine production.

    Conclusions:

    • Cell substrate-based manufacturing offers advantages over traditional calf lymph propagation.
    • Rigorous evaluation of safety and efficacy is crucial for new smallpox vaccines.
    • Regulatory frameworks must adapt to support the development of next-generation vaccines.